In vivo Evaluation of Lymph Nodes Using Quantitative Ultrasound

项目摘要 本申请提出了一项合作研究，由威尔康奈尔医学（WCM）在新的 纽约州约克市，作为牵头组织，与位于纽约州尼斯卡尤纳和斯托尼的GE研究院（格尔）合作 布鲁克医学（SBM）附属于斯托尼布鲁克的纽约州立大学。拟议 该项目解决了对检测淋巴结转移的可靠、高灵敏度方法的需求 (LNs)并将其与原发性淋巴瘤和受良性疾病影响的淋巴结区分开来。这 这一能力将有助于改进疾病的分期和治疗。因此，我们寻求验证现有的 WCM和SBM使用定量超声（QUS）在先前研究中获得了令人鼓舞的结果 通过应用和评估这些有前途的方法， 改进的临床扫描仪，用于从接受医学检查的患者获取超声回波信号数据 需要对可疑淋巴结进行超声引导细针抽吸（FNA）。研究工作包括 更广泛的疾病类型，来自更大和更多样化的患者人群， 在迄今为止的研究中，验证工作将为QUS开发、部署和验证应用程序- 基于在临床扫描仪中实现的LN的检测和表征。成功的验证将 为将基于QUS的LN评价方法纳入临床超声奠定基础 扫描仪这些仪器将能够在手术室中对可疑LN进行术中评估 或术前在检查室检查。合作的研究人员将协同能力， 以下一般方法：WCM将提供项目监督和协调，并将应用、改进和测试 QUS和分类方法;格尔将提供超声仪器，并将开发和 验证扫描仪的QUS应用程序; SBM将招募患者并采集超声和 细胞病理学数据来自接受LN FNA的患者。

Project Summary This application proposes a collaborative study to be performed by Weill Cornell Medicine (WCM) in New York, NY, as the lead organization in collaboration with GE Research (GER) in Niskayuna, NY, and Stony Brook Medicine (SBM) affiliated with the State University of New York in Stony Brook, NY. The proposed project addresses the need for reliable, highly sensitive means of detecting metastases to lymph nodes (LNs) and distinguishing them from primary lymphomas and LNs affected by benign conditions. This capability will allow improved staging and treatment of disease. Accordingly, we seek to validate existing encouraging results obtained in prior studies by WCM and SBM using quantitative-ultrasound (QUS) methods to detect metastases in LNs by applying and evaluating these promising methods using a modified clinical scanner to acquire ultrasonic echo-signal data from patients undergoing medically required ultrasonically guided fine-needle aspirations (FNAs) of suspicious LNs. The study will include a far broader range of disease types from a larger and more-diverse patient population than has been possible in studies to date. Validation efforts will develop, deploy, and validate an application for QUS- based detection and characterization of LNs implemented in a clinical scanner. Successful validation will establish a foundation for incorporation of QUS-based methods for LN evaluation into clinical ultrasonic scanners. Such instruments will be able to evaluate suspicious LNs intra-operatively in the operating room or pre-operatively in the examination room. The collaborating researchers will synergize capabilities in the following general ways: WCM will provide project oversight and coordination and will apply, refine, and test QUS and classification methods; GER will provide ultrasound instrumentation and will develop and validate the QUS application for the scanner; SBM will recruit patients and acquire ultrasonic and cytopathological data from patients undergoing FNAs of their LNs.